August 2008 Volume 4, Issue 8

Volume 4, Issue 8 | August 2008

August 2008

In this Issue

Patent News

Drug Discovery News Placeholder Image

Synergy won’t get you a patent term extension

One way drug companies are compensated for the regulatory burden of seeking FDA approval is the extension of patent terms. One of the eligibility requirements for a patent term extension is that the permission for the commercial marketing or use of the product be the first permitted commercial marketing or use of the product.

Editor's Focus

Drug Discovery News Placeholder Image

How soon does 2015 seem to you?

Seven years ago, Genentech shares were trading for roughly $22 per share and Roche had been the majority owner of the company for a bit more than 10 years. In 2001, with agreements in place that would provide Roche with first choice to pick Genentech’s ripest fruit, I’m sure 2015 seemed forever in the future. But not anymore.

Global News

Drug Discovery News Placeholder Image

Genentech no more?

Roche offers $43.7 billion for remainder of Genetech shares
Drug Discovery News Placeholder Image

Stop the bleeding

Bayer HealthCare acquires Maxygen’s hemophilia assets for up to $120 million
Drug Discovery News Placeholder Image

Summit lands $143M license deal

Summit Corp. plc and California-based BioMarin Pharmaceutical Inc. announced late last month they the companies inked an exclusive worldwide licensing agreement for Summit’s novel preclinical candidate SMT C1100 and all follow-on molecules, which are being developed to treat the fatal genetic disorder Duchenne muscular dystrophy (DMD).
Drug Discovery News Placeholder Image

Tropical diseases tested

Upstream Biosciences, McGill University to collaborate on tropical disease treatment testing
Drug Discovery News Placeholder Image

Immunomedics, Nycomed in veltuzumab deal

Immunomedics Inc. and Nycomed GmbH recently announced a license and collaboration agreement providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, Immunomedics’ humanized anti-CD20 antibody in a subcutaneous formulation for the treatment of all non-cancer indications.

Research & Development

Drug Discovery News Placeholder Image

Wider gap in generics

Teva snaps up Barr for $7.4 B
Drug Discovery News Placeholder Image

Cinryze and synergy

ViroPharma acquires Lev Pharmaceuticals and inflammatory disease program
Drug Discovery News Placeholder Image

No-nonsense drug discovery

Genzyme and PTC Therapeutics to develop small molecule for genetic diseases
Drug Discovery News Placeholder Image

Go fish

Znomics, OHSU use zebrafish screening to identify inflammatory disease therapeutics
Drug Discovery News Placeholder Image

FAST pharma friends

Lilly acquires oncology biotech SGX Therapeutics for $64 million

Genomics & Proteomics

Drug Discovery News Placeholder Image

A nose for opportunity

Nastech becomes mdRNA and moves RNAi tech ahead of nasal delivery
Drug Discovery News Placeholder Image

Protein power

Althea Technologies and Protein'eXpert accord connects early- and late-stage needs for client projects
Drug Discovery News Placeholder Image

Wake up and die

Duke researchers may be on to a way to activate herpes long enough to kill it
Drug Discovery News Placeholder Image

U.W.’s new fly in the ointment

Research uncovers new ‘pressure points’ against flu
Drug Discovery News Placeholder Image

U of Minn. spearheads guidance on incidental findings

When one thinks of byproducts of pharmaceutical research, biomedical waste might be the first thing that comes to mind for most, but an increasing area of concern is the leftover incidental health findings, says Susan Wolf, J.D., who chairs the University of Minnesota’s Consortium on Law and Values in Health, Environment and the Life Sciences.

Informatics

Drug Discovery News Placeholder Image

High-throughput triple team

Applied Bio and Integromics collaborate with Novartis on high-throughput analysis platform
Drug Discovery News Placeholder Image

No gene left behind

Sophic and Biomax receive funds to complete NCI's Cancer Gene Index Project
Drug Discovery News Placeholder Image

Finding the needle in the haystack

Thermo Fisher and Genedata form mass spec partnership
Drug Discovery News Placeholder Image

Out with the old

Channing Lab phases out Legacy LIMS with LabVantage’s SAPPHIRE
Drug Discovery News Placeholder Image

British bioscience booster shot

GSK, Univ. of Manchester ally to bridge research gaps in U.K.

Automation & Instrumentation

Drug Discovery News Placeholder Image

Short-hairpin, long view

Thermo Fisher buys Open Biosystems and adds company's shRNA lentiviral library to its growing RNAi portfolio
Drug Discovery News Placeholder Image

Paying the price for PCR

Qiagen buys Australia’s Corbett Life Sciences in deal that could eventually top $130 million
Drug Discovery News Placeholder Image

Affinity for acquisitions

Thermo Fisher buys Affinity BioReagents
Drug Discovery News Placeholder Image

Iongate’s SURFE²R is up

IonGate taps Artel to spearhead adoption and application of SURFE²R technology in North America

Feature

Drug Discovery News Placeholder Image

Rise of next-gen genomics

The Human Genome Project was just the start; NIH is pushing hard on the genomics envelope
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue